Day 1: February 27, 2017
|
| 7:45 AM |
Breakfast and Registration |
| 8:30 AM |
Introduction and Welcome Remarks
Representative, Mushett Family Foundation
Representative, Science, Science Translational Medicine, and Science Immunology
Representative, The New York Academy of Sciences |
| 8:55 AM |
Day 1 Keynote Address:
Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities and Prospects for A Cure
James P. Allison, PhD, The University of Texas MD Anderson Cancer Center |
Session 1: Assessment of Current Therapeutic Approaches in Cancer Immunotherapy: Successes and Challenges
|
| 9:40 AM |
Title to Be Announced
Phillip D. Greenberg, MD, University of Washington |
| 10:05 AM |
In situ Vaccination for the Treatment of Cancer
Nina Bhardwaj, MD, PhD, Mount Sinai School of Medicine |
| 10:30 AM |
Treating the Tumor and Treating the Host
Ronald Levy, MD, Stanford University |
| 10:55 AM |
Networking Coffee Break |
Session 2: Evaluation of Combination Therapy Strategies to Improve Clinical Outcomes
|
| 11:25 AM |
Title to Be Announced
Jedd D. Wolchok, MD, Memorial Sloan Kettering Cancer Center |
| 11:50 AM |
The Promise of Epigenetic Therapies for Enhancing the Efficacy of Immune Checkpoint Therapy
Stephen B. Baylin, MD, Johns Hopkins University |
| 12:15 PM |
HPV Theraputic Vacccines: Where Are We Now and Where Are We Going?
Cornelia (Connie) Liu Trimble, MD, Johns Hopkins University |
| 12:40 PM |
Networking Lunch and Poster Viewing |
| 12:55 PM |
Underrepresented Minorities, Women, and Early Career Investigator Career Development Workshop and Lunch Running Concurrently with the Networking Lunch
For Graduate Students, Post-doctoral Fellows, and Junior Faculty
Editor’s Guide to Writing and Publishing Your Paper
Angela Colmone, PhD, Senior Editor, Science Translational Medicine
Kristen Mueller, PhD, Senior Editor, Science
Yevgeniya Nusinovich, MD, PhD, Associate Editor, Science Translational Medicine |
Session 3: Identification of Relevant Prognostic and Predictive Biomarkers for the Development of Immune-Monitoring Strategies
|
| 2:00 PM |
Inflammation and Cancer: Fueling Response and Resistance of Immunotherapies
Lisa Coussens, PhD, Oregon Health Sciences University |
| 2:25 PM |
High-throughput Single-Cell Analysis for T-Cell Receptor Ligands and Sequences
Mark Davis, PhD, Stanford University |
| 2:50 PM |
Response and Resistance to PD-1 Blockade Therapy
Antoni Ribas, MD, PhD, University of California Los Angeles |
| 3:15 PM |
Networking Coffee Break |
Session 4: Hot Topic Short Talks
|
| 3:40 PM |
Short Talk Selected from Submitted Abstracts |
| 3:55 PM |
Short Talk Selected from Submitted Abstracts |
Session 5: Development of Strategies to Overcome Immune Tolerance
|
| 4:10 PM |
Title to Be Announced
Thomas Gajewski, MD, PhD, University of Chicago |
| 4:35 PM |
Molecular and Epigenetic Programs Underlying CD8 T Cell Dysfunction in Solid Tumors
Andrea Schietinger, PhD, Memorial Sloan Kettering Cancer Center |
| 5:00 PM |
Targeting FoxP3+ T-cells in Cancers; Friends or Foes?
Hiroyoshi Nishikawa, MD, PhD, National Cancer Center Hospital, Japan |
| 5:25 PM |
Panel Discussion |
| 5:50 PM |
Closing Remarks |
| 6:00 PM |
Poster Session 1 and Networking Reception |
| 7:00 PM |
Day 1 Adjourns |
Day 2: February 28, 2017
|
| 8:00 AM |
Breakfast and Registration |
| 8:00 PM |
Underrepresented Minorities, Women, and Early Career Investigator Mentoring Breakfast Running Concurrently with the General Breakfast |
Session 6: Clinical Research Break Out Sessions
|
| 9:00 AM |
Breakout Group 1: How to Manage Toxicities in Cancer Immunotherapy?
Jedd D. Wolchok, MD, Memorial Sloan Kettering Cancer Center |
|
Breakout Group 2: How to Incorporate Biomarkers into Early Phase Immunotherapy Trials?
Jonathan Cebon, MBBS, PhD, FRACP, Olivia Newton-John Cancer and Wellness Centre |
|
Breakout Group 3: What are the Latest Strategies for Cancer Immunotherapy Development — a Pharmaceutical Industry Perspective?
Ira Mellman, PhD, Genentech |
| 10:00 AM |
Networking Coffee Break |
Session 7: Optimizing Incorporation of Cancer Genomics and Epigenomics into Immunotherapy Research and Clinical Strategies
|
| 10:30 AM |
Title to Be Announced
Steven Rosenberg, MD, PhD, National Cancer Institute, U.S. National Institutes of Health |
| 10:55 AM |
Title to Be Announced
Michele Maio, MD, PhD, University Hospital, Sienna, Italy |
| 11:20 AM |
Using Cancer-specific Neoantigens to Personalize Cancer Immunotherapy
Robert Schreiber, PhD, Washington University |
| 11:45 AM |
Networking Lunch and Poster Session 2 |
Session 8: Targeting T-cells in Cancer Immunotherapy
|
| 1:15 PM |
Regulatory T-cells and Strategies for Inhibition for Cancer Therapy
Alexander Rudensky, PhD, Memorial Sloan Kettering Cancer Center |
| 1:40 PM |
Use of Engineered Chimeric Antigen Receptors for Leukemia Treatment
Crystal Mackall, MD, Stanford University |
| 2:05 PM |
Title to Be Announced
Kunle Odunsi, MD, PhD, Roswell Park Cancer Institute |
| 2:30 PM |
Networking Coffee Break |
Session 9: Hot Topic Short Talks
|
| 3:00 PM |
Short Talk Selected from Submitted Abstracts |
| 3:15 PM |
Short Talk Selected from Submitted Abstracts |
Session 10: Emerging Technologies in Cancer Immunotherapy
|
| 3:30 PM |
Title to Be Announced
Laurence Zitvogel, MD, PhD, Institut National de la Santé et Recherche Médicale |
| 3:55 PM |
Emerging Technologies in Cancer Immunotherapy
Carl June, MD, University of Pennsylvania |
| 4:20 PM |
Closing Remarks |
| 4:30 PM |
Conference Adjourns |
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
FrasonFrancis
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply